Edgewise’s New Cardiomyopathy Drug Clears Phase 2, as EDG-7500 Pushes Into Both Types of HCM

Treatment of hypertrophic cardiomyopathy in recent years has no longer relied only on symptom control, but has gradually moved toward directly modulating the mechanism of cardiac muscle contraction. Edgewise Therapeutics’ EDG-7500 met its goals in a Phase 2 trial, giving the biotech company, which has recently shifted its focus toward cardiovascular disease, a ticket into pivotal testing.

BioPharma Dive reported that EDG-7500, in the Phase 2 study called Cirrus-HCM, improved disease-related measures and symptom scales in patients with obstructive and non-obstructive hypertrophic cardiomyopathy. The mid-stage study was primarily designed as a safety trial, but it also included efficacy signals such as quality of life, symptoms, and biomarkers as the basis for subsequent clinical development.

Investor’s Business Daily cited data showing that 74% of obstructive patients and 88% of non-obstructive patients achieved normalization of NT-proBNP or at least a 50% reduction. NT-proBNP is a commonly used blood marker of cardiac stress and heart failure risk; its decline does not mean improved clinical outcomes have been proven, but it can provide clues that cardiac burden may have been reduced.

Readable changes also appeared on the symptom side. Reports said obstructive patients improved by an average of 24 points on the KCCQ cardiac quality-of-life questionnaire, while non-obstructive patients improved by 13 points; NYHA functional class improved in about 70% and at least 64% of patients, respectively. These figures mean EDG-7500 is not staying only at the level of laboratory markers, but the Phase 2 trial was limited in size and still cannot answer harder questions such as hospitalization, death, or long-term preservation of cardiac function.

Safety is a central test for this type of drug. BioPharma Dive noted that EDG-7500 showed no dose-related decline in left ventricular ejection fraction; this point is especially sensitive for cardiac myosin inhibitors, because excessive suppression of cardiac contraction may bring risk. Two cases of atrial fibrillation occurred in the study, which Investor’s Business Daily said accounted for about 3.8% of participants, and trial investigators judged them unrelated to treatment; however, events of this kind still need stricter tracking in larger and longer studies.

EDG-7500’s competitive positioning is more complex than the success or failure of a single trial. Existing or recently approved drugs in the same class, such as Bristol Myers Squibb’s Camzyos and Cytokinetics’ Myqorzo, have market labels mainly concentrated in obstructive HCM; Edgewise is trying to enter both obstructive and non-obstructive disease at the same time. If efficacy in non-obstructive patients can be maintained in late-stage trials, it would give the drug’s clinical narrative more weight.

The market reaction showed that investors did not view the data as a flawless victory. Investor’s Business Daily reported that Edgewise shares swung sharply after the data were released, moving intraday between double-digit gains and losses before closing down 3.6%. This reaction reflects not trial failure, but repricing under high expectations: safety and symptom signals can support moving forward, but whether the drug is better than competitors and whether its applicable scope is broader still require Phase 3 trials to provide clearer answers.